Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy

Natalja Haninger-Vacariu, Christof Aigner, Renate Kain, Zoltán Prohászka, Martina Gaggl, Georg A. Böhmig, Leah Charlotte Piggott, Raute Sunder-Plassmann, Gere Sunder-Plassmann, and Alice Schmidt

In patients with pregnancy-associated complement gene variant–mediated thrombotic microangiopathy (cTMA), terminal complement blockade is used for treatment of cTMA flares during pregnancy or following delivery. We report pregnancy and delivery outcomes of 2 genetically high-risk patients with cTMA, including 1 kidney transplant recipient, during ongoing eculizumab therapy. In both patients, the first manifestation of cTMA occurred independent from pregnancy. One patient has a history of 2 uneventful pregnancies with prophylactic plasma infusions, and the other has a history of early abortion during long-term eculizumab therapy following kidney transplantation. Overall, pregnancy and delivery outcomes under ongoing eculizumab therapy in our 2 patients with preserved kidney function were excellent as compared with other patients reported in the literature. Eculizumab plasma concentrations were maintained in the therapeutically range during pregnancy and were also detectable in cord blood. Results of cord blood analysis showed deficient complement activity, with low factor and regulator levels, most likely reflecting the age of the neonates and presence of eculizumab in cord blood. In conclusion, pregnancy during ongoing eculizumab treatment appeared to be safe in 2 women with a history of high-risk genetic cTMA and excellent kidney function, even following kidney transplantation.

© 2020 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

INTRODUCTION

A history of complement gene variant–mediated thrombotic microangiopathy (cTMA) bears an increased risk for TMA relapse during pregnancy, leading to miscarriage, poor delivery outcomes, and end-stage kidney disease. Pregnancy is generally discouraged in these women. Therefore, preventive plasma therapy has been used in the past during pregnancy for several patients who wanted to have children despite discussions of the risks involved. More recently, eculizumab was used to treat cTMA flares during pregnancy (Table S1) and after delivery (Table S2), but also in a preventive setting, in which patients with cTMA became pregnant during ongoing eculizumab therapy. Servais et al reported 5 pregnancies in 3 women during ongoing eculizumab therapy and showed rather poor pregnancy and delivery outcomes. Complications included 1 abortion and 2 growth retardations, and all 4 neonates were small for gestational age. Each of the reported women experienced either HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome or, in 2 cases, preeclampsia. Duval et al recently reported another pregnancy during ongoing eculizumab treatment in a patient who delivered a preterm child by caesarean section at gestational week 27 with plasma and higher dose eculizumab rescue therapy.

From the Vienna TMA cohort (Fig S1), we identified pregnancies in patients with cTMA and we report excellent pregnancy and delivery outcomes of 2 pregnancies in 2 genetically high-risk patients with cTMA with well-preserved kidney function, including a kidney transplant recipient, during ongoing eculizumab therapy.

CASE REPORTS

Case 1

A white woman with an approximate 10-year history of cTMA underwent kidney biopsy for worsening kidney function in her late 20s. This biopsy showed acute and chronic glomerular and interstitial arteriolar TMA and she acutely required dialysis. Despite plasma exchange, she remained dialysis dependent and received a deceased donor kidney graft 4 years later. Molecular genetic analysis revealed the presence of: (1) a rare variant in CFH (p.C1032X, heterozygous), (2) the CD46ggaac risk haplotype (homozygous), and (3) the CFH H8 haplotype (heterozygous). Due to the genetically high-risk scenario, she received peritransplantation plasma exchange followed by fortnightly plasma infusions for prevention of cTMA recurrence. Kidney function was excellent within a few days after surgery (serum creatinine, 1.5 mg/dL 7 days after transplantation). She remained on treatment with blood pressure–lowering medication using a triple combination of antihypertensive drugs. Three months after...
transplantation, allergic reactions with recurrent severe maculopapular rash prompted a switch from plasma therapy to complement inhibition with eculizumab (900 mg every week for 4 weeks followed by 1,200 mg fortnightly). Serum creatinine level was in the reference range at this time (0.89 mg/dL).

Shortly after transplantation, the patient wanted to become pregnant. The risks for the mother and baby, such as pregnancy in kidney transplant recipients and pregnancy with a history of cTMA, were discussed extensively with the patient and the family. Immunosuppressive therapy was switched from tacrolimus to cyclosporine A because of hair loss and later from mycophenolate mofetil to azathioprine for prevention of miscarriage and congenital defects. Three months after conversion, immunosuppression included cyclosporine A at 75 mg twice daily (trough level, 50-80 ng/mL), azathioprine at 25 mg once daily, and prednisolone at 5 mg once daily. Kidney function was excellent (serum creatinine remained between 0.9 and 1.1 mg/dL and urinary protein-creatinine ratio, <200 mg/g) and blood pressure was well controlled (<130/80 mm Hg) with triple blood pressure–lowering therapy. Her first pregnancy was diagnosed at 7 weeks of gestation, but unfortunately ended with a spontaneous abortion around 12 weeks of gestation. Clinical and laboratory details are summarized in Tables 1 and 2.

Five months later, the patient reported her second pregnancy at 7 weeks of gestation. The frequency of eculizumab doses was increased in the second trimester (900 mg every week starting during gestational week 17). Kidney function remained stable but proteinuria increased to protein excretion >1 g/24 h, and the need for antihypertensive medications increased at the same time at 36+0 weeks of gestation. However, the SFLT1/PLGF (soluble fms-like tyrosinkinase 1 to placental growth factor) ratio in serum, a risk marker for preeclampsia, remained low. She delivered a healthy child by vaginal delivery the following week at 37+0 weeks of gestation (Table 1). The clinical course and results of laboratory tests during and after pregnancy are indicated in Tables 2 and 3.

**Case 2**

A white woman with a history of hemolytic uremic syndrome starting at 3 years old became pregnant for the third time in her mid-20s. Since age 3 years, she had experienced multiple episodes of acute kidney injury attributed to TMA. These resolved without plasma therapy, with a return of kidney function to baseline. At age 14 years, the 23rd TMA episode resulted in acute kidney failure and necessitated a total of 6 plasma exchanges until normalization of kidney function. Later, her first 2 pregnancies in her late teens and early 20s were managed with prophylactic plasma therapy (case A.1, Gaggl et al, 2018) and resulted in vaginal delivery of 2 healthy children. During both pregnancies, she showed no signs of complement activation as evidenced by microangiopathic hemolysis, but she developed proteinuria with protein excretion >1 g/24 h at the end of the second pregnancy that did not resolve completely after delivery. However, serum creatinine level remained normal. Antihypertensive therapy was not necessary during her first pregnancy, although during the second pregnancy she received nifedipine, which was replaced by lisinopril after her second delivery due to proteinuria. Genetic testing revealed disease-causing variants in CFI (p.G342E; heterozygous) and CD46 (p.D257Vfs*41; heterozygous), as well as the CFH H3 haplotype (heterozygous). Furthermore, she carries the p.R102G/p.P314L haplotype in C3, which is a risk factor for dense deposit disease.

One year after the patient’s second delivery, she presented with acute TMA accompanied by persistent proteinuria. Shortly before her third pregnancy, she agreed to undergo a kidney biopsy owing to proteinuria and another TMA flare triggered by a gastrointestinal infection. Pathologic examination revealed signs of chronic and also acute TMA, as well as C3, immunoglobulin M, and C1q deposits. At this time, complement inhibition with eculizumab was initiated (900 mg every week for 4 weeks followed by 1,200 mg fortnightly) and urinary protein-creatinine ratio significantly decreased from 1,727 to 509 mg/g thereafter.

Eculizumab treatment was continued with 1,200 mg fortnightly during the patient’s third pregnancy in the same year, which was confirmed at gestational week 8. Proteinuria increased to protein excretion of ~1 g/24 h at the end of pregnancy. However, the SFLT1/PLGF ratio remained low. Blood pressure–lowering medication was changed from lisinopril to methyldopa before pregnancy and was not changed during pregnancy. At gestational week 40+3, she delivered a healthy child after an uneventful pregnancy (Table 1). The clinical course and results of laboratory tests during and after this pregnancy are indicated in Tables 2 and 3.
DISCUSSION

Our center’s experience based on 52 pregnancies in women with cTMA and now 2 further successful pregnancies under maintenance eculizumab therapy strongly suggests that pregnancies in women with cTMA have an excellent prognosis, even in women with high-risk mutations.

However, data for the therapeutic use of eculizumab during pregnancy or breastfeeding in patients with cTMA are scarce (see also Tables S1 and S2). Limited data for malformations indicate no increased risk compared with non-eculizumab-treated mothers. However, eculizumab may cross the placental barrier and may cause terminal complement inhibition in the fetal circulation. To date, no evidence exists that eculizumab is excreted in human breast milk. Therefore, an individual risk-benefit analysis is recommended before starting and during treatment of pregnant or breastfeeding women with eculizumab.

The primary concern with terminal complement blockade is increased susceptibility to infection with encapsulated organisms, particularly Neisseria species infections. Meningococcal vaccination is considered mandatory and long-term antibiotic prophylaxis is recommended for the duration of treatment and up to 3 months after withdrawal. This issue was discussed with our patients and according to the standard of care at our institution, both were vaccinated together with antibiotic prophylaxis given for 2 weeks at the start of eculizumab therapy. Other concerns include hepatotoxicity in association with eculizumab therapy as reported in children and adults. Furthermore, deposition of eculizumab has been reported in individuals with C3 glomerulopathy or cTMA and its significance is currently unknown.

Most recently, a 10-year pharmacovigilance study of eculizumab reported 434 cases of eculizumab exposure in pregnant women. Among 260 cases with known outcomes, 70% resulted in live births. With respect to eculizumab exposure of newborns, only 2 studies reported eculizumab concentrations in cord blood or in neonates born to women with cTMA, one of which was negative. In our 2 babies, eculizumab could be detected in cord blood (Table 3), but further analysis was not done on the neonates. Results of complement-related tests in cord blood showed deficient complement activity, with low

| Table 2. Time Course of Laboratory Results and Clinical Details of 3 Pregnancies During Ongoing Eculizumab Therapy in 2 Patients With cTMA |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| **Time of blood test, gestational wk** | **Patient 1 (KTX), Pregnancy 1** | **Patient 1 (KTX), Pregnancy 2** | **Patient 2, Pregnancy 1** | **Patient 2, Pregnancy 2** |
| **SBP, mm Hg** | 127 | 104 | 141 | 133 | 122 | 149 | 135 | 124 | 121 | 146 | 122 |
| **DBP, mm Hg** | 76 | 70 | 89 | 86 | 87 | 99 | 69 | 73 | 91 | 81 | 94 |
| **Serum creatinine, mg/dL** | 0.97 | 0.88 | 0.91 | 1.02 | — | 0.97 | 0.82 | 0.72 | 0.76 | 0.96 | 0.82 |
| **Urinary PCR, mg/g** | 76 | 101 | 269 | 1,818 | — | 1,651 | 390 | 359 | 1,386 | ND | 1,355 |
| **Platelets, ×10³/μL** | 250 | 257 | 279 | 263 | — | 302 | 217 | 204 | 187 | 221 | 304 |
| **Lactate dehydrogenase, U/L** | ND | 163 | 154 | 161 | — | 179 | 159 | 213 | ND | 187 | 220 |
| **Haptoglobin, mg/dL** | 37.4 | 366 | <12 | <12 | — | 56.4 | 94.8 | 84.6 | 77.6 | ND | 146 |
| **SFLT1/PLGF** | ND | 50 | 5.43 | 6.7 | — | ND | 2.68 | ND | ND | ND | ND |
| **TCA, classical pathway, CH50/mL** | 9 | 14 | 14 | 4 | 9 | 9 | 2 | 2 | ND | ND | 11 |
| **TCA, alternative pathway, %** | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | ND | ND | 0 |
| **Complement C3, g/L** | 0.73 | 0.88 | 1.19 | 1.31 | 1.15 | 0.91 | 1.31 | 1.09 | ND | ND | 1 |
| **Complement C4, g/L** | 0.24 | 0.33 | 0.37 | 0.3 | 0.3 | 0.41 | 0.42 | 0.33 | ND | ND | 0.38 |
| **Complement factor H antigen, mg/L** | 239 | 345 | 256 | 319 | 267 | 356 | 1,107 | 738 | ND | ND | 441 |
| **Complement factor I antigen, %** | 53 | 93 | 96 | 101 | 79 | 94 | 100 | 98 | ND | ND | 88 |
| **Complement factor B antigen, %** | 63 | 96 | 85 | 101 | 102 | 75 | 94 | 91 | ND | ND | 71 |
| **sC5b-9, ng/mL** | 697 | 554 | 307 | 245 | 385 | 1,128 | 233 | 320 | ND | ND | 401 |
| **Serum free eculizumab level, μg/mL** | ND | 81 | 240 | 157 | 120 | 116 | 60 | 76 | ND | ND | 95 |
| **Medication, daily dose, mg** | | | | | | | | | | | |
| **Cyclosporine A** | 150 | 200 | 200 | 250 | 250 | 250 | — | — | — | — | — |
| **Azathioprine** | 25 | 25 | 25 | 25 | 25 | 25 | — | — | — | — | — |
| **Steroid** | 5 | 5 | 5 | 5 | 5 | 5 | — | — | — | — | — |
| **Nifedipine** | 60 | 60 | 60 | 60 | 60 | 60 | — | — | — | — | — |
| **Metoprolol** | 75 | 75 | 0 | 100 | 100 | 100 | — | — | — | — | — |
| **Labetalol** | 300 | 300 | 300 | 300 | 300 | 300 | — | — | — | — | — |
| **Methyldopa** | — | — | — | — | — | — | 500 | 500 | 500 | 500 | 500 |

**Note:** Conversion factor for units: serum creatinine in mg/dL to μmol/L, ×88.4. Abbreviations: cTMA, complement gene variant–mediated thrombotic microangiopathy; DBP, diastolic blood pressure; Del, delivery; KTX, kidney transplantation; ND, not done; PCR, protein-creatinine ratio; SBP, systolic blood pressure; sC5b-9, soluble terminal complement complex; SFLT1/PLGF, soluble fms-like tyrosinkinase 1 to placental growth factor ratio; TCA, total complement activity.

*±2 weeks.*
factor and regulator levels in the absence of overactivation, reflecting most probably the age of the neonates and the presence of eculizumab in cord blood (Table 3). We recommend close monitoring of the child in the postpartum period because possible neonatal consequences of complement blockade are unknown. Histologic examination of placentas from both patients showed no pathologic finding.

Recurrence is high, with an incidence of 20% in women with preexisting cTMA, which causes significant maternal mortality and morbidity. However, in our genetically high-risk patients with cTMA with preserved kidney function, administration of eculizumab during the whole pregnancy was well tolerated and associated with excellent pregnancy and delivery outcomes. Though our patients had gene mutations, it is worth mentioning that the presence or the nature of complement gene mutations on the course of pregnancy-associated cTMA appears to be variable. Some data support that women with complement gene mutations progressed more frequently to dialysis-dependent kidney failure. This contrast is most likely related to the decreased kidney function, more severe proteinuria, and hypertension in the patients of Servais et al, which certainly poses further risks for poor pregnancy outcomes among these women with preeclampsia-related cTMA possibly complicating the picture.

It is also important to point out that although the safety of eculizumab in pregnancy has been established, especially given its use in patients with paroxysmal nocturnal hemoglobinuria and a few cases of cTMA in pregnancy, we cannot lose sight of the cost of treatment. An alternate strategy includes expectant management with immediate treatment with eculizumab should an episode of cTMA occur. This seems to be gaining traction.

In conclusion, ongoing eculizumab treatment appeared to be safe in 2 pregnant women with a history of genetically high-risk cTMA, even following kidney transplantation. Pregnancy and delivery outcomes were excellent in these 2 reported pregnancies.

| Table 3. Results of Complement Laboratory Analyses From Cord Blood of 2 Neonates Born to Mothers With cTMA Under Ongoing Eculizumab Therapy |
|---------------------------------|-----------------|-----------------|-----------------|
| **Outcome**                     | **Case 1**      | **Case 2**      | **Adult Reference** |
| TCA classical pathway, CH50/mL  | 14              | 26              | 48-103           |
| TCA alternative pathway, %      | 0               | 0               | 70-105           |
| Complement C3, g/L              | 0.5             | 0.71            | 0.9-1.8          |
| Complement C4, g/L              | 0.09            | 0.11            | 0.15-0.55        |
| Complement factor H antigen, mg/L | 64             | 179             | 250-880          |
| Complement factor I antigen, %  | 68              | 54              | 70-130           |
| Complement factor B antigen, %  | 59              | 49              | 70-130           |
| SC5b-9, ng/mL                   | 139             | 130             | 110-252          |
| Serum free eculizumab level, μg/mL | 29              | 3               | NA              |
| Time since last eculizumab therapy, d | 3              | 4               | NA              |

Genetic variants of the newborns

| Gene   | Variant                        |
|--------|--------------------------------|
| CFH    | p.C1032X, het                  |
| CFH haplotype | H3, het                   |
| CFI    | p.G342E, het                  |
| CD46   | ggaac, hom                     |
| CD46 haplotype | ggaac, het              |

Abbreviations: —, no variant found; cTMA, complement gene variant-mediated thrombotic microangiopathy; het, heterozygous; hom, homozygous; NA, not applicable; SC5b-9, soluble terminal complement complex; TCA, total complement activity.

SUPPLEMENTARY MATERIAL

Supplementary File (PDF)

Figure S1: Patient disposition in the Vienna TMA cohort as of September 2019

Table S1: Eculizumab therapy for p-cTMA flare during pregnancy

Table S2: Eculizumab therapy for p-cTMA flare after delivery or abortion

ARTICLE INFORMATION

Authors’ Full Names and Academic Degrees: Natalja Haninger-Vacariu, MD, MSc, Christof Aigner, MD, Renate Kain, MD, Zoltán Prohászka, MD, Martina Gaggl, MD, Georg A. Böhmig, MD, Leah Charlotte Piggott, Raute Sunder-Plassmann, MD, Gere Sunder-Plassmann, MD, and Alice Schmidt, MD.
Case Report

Authors’ Affiliations: Division of Nephrology and Dialysis, Department of Medicine III (NH-V, CA, MG, GAB, LCP, GS-P, AS) and Clinical Institute of Pathology (RK), Medical University of Vienna, Vienna, Austria; Research Laboratory, 3rd Department of Internal Medicine, and MTA-SE Research Group of Immunology and Hematology, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary (ZP); and Genetics Laboratory, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria (RS-P).

Address for Correspondence: Natalja Haninger-Vacariu, MD, MSc, Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. E-mail: natalja.haninger-vacariu@meduniwien.ac.at

Support: None.

Financial Disclosure: The authors declare that they have no financial interests.

Acknowledgements: We are grateful to our patients who fully supported the data collection of their pregnancies and their babies for this article and to Dorottya Csuka, Eszter Trojn, and Nóra Veszeli for complement determinations and serum free eculizumab measurements.

Patient Consent: The authors declare that they have obtained consent from the patients discussed in the report.

Peer Review: Received July 27, 2019. Evaluated by 1 external peer reviewer, with direct editorial input from an Associate Editor and the Editor-in-Chief. Accepted in revised form December 12, 2019.

REFERENCES

1. Bruel A, Kavanagh D, Noris M, et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol. 2017;12(8):1237-1247.
2. Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018;93(2):450-459.
3. Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859-867.
4. Gaggl M, Aigner C, Csuka D, et al. Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2018;29(3):1020-1029.
5. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J. 2019;12(3):333-337.
6. Servais A, Devillard N, Fremeaux-Bacchi V, et al. Atypical haemolytic uremic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant. 2016;31(12):2122-2130.
7. Duval A, Olagne J, Cognard N, et al. Pregnancy in a kidney transplant woman under treatment with eculizumab for atypical hemolytic uremic syndrome: is it safe? Kidney Int Rep. 2019;4(5):733-739.
8. Fontana F, Alfano G, Bardhushti E, et al. Relapse of atypical hemolytic uremic syndrome during pregnancy in a patient on eculizumab maintenance treatment: a case report. Am J Case Rep. 2019;20:1460-1465.
9. Sarro L, Tufano A, Marotti GM, Martinelli P, Balletta MM, Russo D. Eculizumab in pregnancy: a narrative overview. J Nephrol. 2019;32(1):17-25.
10. EMA. Soliris-EPAR-product information. https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. Accessed November 6, 2019.
11. Oruc A, Ayar Y, Vuruskan BA, et al. Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia. 2018;38(4):448-450.
12. Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol. 2012;23(7):1229-1237.
13. Cassol CA, Brodsky SV, Satoskar AA, Cataland S, Nadasdy T. Eculizumab deposits in vessel walls in thrombotic microangiopathy. Kidney Int. 2019;96(3):761-768.
14. Socie G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297-310.
15. Duineveld C, Wijnsmra KL, Volokhina EB, van den Heuvel LPB, van de Kar N, Wetzels JFM. Placental passage of eculizumab and complement blockade in a newborn [letter]. Kidney Int. 2019;95(4):996.
16. Schaefer F, Ardissono G, Ariceta G, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408-418.
17. Gatzka C, Bremerich D, Kaufmann M, Ahr A. [Isolated decrease of haptoglobin during pregnancy: diagnosis by chance or pathological?]. Zentralbl Gynakol. 2002;124(2):120-122.
18. Areekul S, Kitiyanee U, Ukoskit K. Serum haptoglobins in pregnancy. Southeast Asian J Trop Med Public Health. 1975;6(4):567-572.
19. Piccoli GB, Zakharova E, Attini R, et al. Pregnancy in chronic kidney disease: need for higher awareness. A pragmatic review focused on what could be improved in the different CKD stages and phases [published online November 5, 2018]. J Clin Med. https://doi.org/10.3390/jcm7110415.
20. Wijnsmra KL, Duineveld C, Wetzels JFM, van de Kar N. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019;34(11):2261-2277.